Results 51 to 60 of about 28,823 (297)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study

Journal of Diabetes Investigation, 2021
Aims/Introduction We recently reported the beneficial effect of the combination of sodium–glucose cotransporter 2 inhibitor and dipeptidyl peptidase‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus. Additional favorable
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya, Ikumi Shigesawa, Kenichi Tsuchida, Shingo Yanagiya, Hiraku Kameda, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Naoki Nishimoto, Tatsuya Atsumi, Hideaki Miyoshi   +20 more
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes:What have we learned from the CARMELINA trial? [PDF]

, 2019
Dipeptidyl peptidase-4 inhibitors are a relatively new class of oral anti-hyperglycaemic drugs to treat type 2 diabetes through prevention of degradation of incretins by the dipeptidyl peptidase-4 enzyme.
Jandeleit-Dahm, Karin A. M., Hanssen, Nordin M. J., Hanssen, Nordin M.J., Jandeleit-Dahm, Karin A.M.   +3 more
core   +1 more source

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis

BMC Cancer, 2019
Background Chemotherapy-induced alimentary mucositis (AM) is difficult to prevent and treatment is rarely effective. Recent study have been showed that glucagon-like peptide (GLP)-1 and GLP-2 has protective in chemotherapy-induced AM.
Jung Min Lee, In Kyung Yoo, Jae Min Lee, Seung Han Kim, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim   +12 more
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy [PDF]

, 2010
Mary Elizabeth Cox1, Jennifer Rowell1, Leonor Corsino1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology,
Mary Elizabeth Cox, et al, Jennifer Rowell, Leonor Corsino   +3 more
core  

Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. [PDF]

, 2006
Udgivelsesdato: 2006-Jun-1Dipeptidyl peptidases 8 and 9 have been identified as gene members of the S9b family of dipeptidyl peptidases. In the present paper, we report the characterization of recombinant dipeptidyl peptidases 8 and 9 using the ...
Christensen, Jesper, Nielsen, Per F, Branner, Sven, Kanstrup, Anders B., Wagtmann, Nicolai, Kanstrup, Anders B, Bjelke, Jais R, Bjelke, Jais R., Nielsen, Per F., Rasmussen, Hanne B., Rasmussen, Hanne B   +10 more
core   +1 more source

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats [PDF]

, 2016
Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess ...
Borde MK, Maheshwari U, Suman RK, Mohanty IR, Deshmukh YA   +4 more
core  

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema [PDF]

Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals.
Harris, S, Shreevatsa, A, Gainer, JV, Brown, NJ, Byrd, JB, Summar, M, Touzin, K, Adam, A, Putlur, P, Yu, C, Nadeau, J   +10 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin [PDF]

, 2016
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X, Varnado OJ, Bae JP, Jiang D, Liu D   +4 more
core  

Genetically Targeted Dipeptidyl Peptidase-4 Inhibitor Use in a Patient with a Novel Mutation of MODY type 4 [PDF]

, 2015
Maturity onset diabetes of the young (MODY) is a rare form of diabetes mellitus typically seen in young adults that results from pancreatic beta-cell dysfunction. MODY4 is a rare subtype caused by a PDX1 mutation.
Christian Mangrum, Vijay Shivaswamy, Eric Rush   +2 more
core   +1 more source